CVS CVS Health (CVS) Insider Trading, Ownership & Congress Trades
Wholesale & Retail · Retail-drug stores and proprietary stores · CIK 0000064803
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
1,110
13F, latest reported quarter
What the filings say about CVS
Insiders, 180 days
-$323.7M net sold
2 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 2 sold
Latest: sale, 2025-11-21
CVS Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, CVS HEALTH Corp insiders sold a net $323.7M of stock across 62 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on May 20, 2026.
- The trade is 7.7% of the 4,824,799 shares held after it.
- 1 other insider sold within 30 days.
- 1,110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ROBBINS LARRY sold about $34.6M of CVS on May 21, 2026; 1 other insider sold within 30 days and 1,110 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 19, 2026.
- The trade is 1.3% of the 5,196,061 shares held after it.
- 1 other insider sold within 30 days.
- 1,110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ROBBINS LARRY sold about $6.4M of CVS on May 20, 2026; 1 other insider sold within 30 days and 1,110 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 19, 2026.
- The trade is 0.0% of the 5,195,261 shares held after it.
- 1 other insider sold within 30 days.
- 1,110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ROBBINS LARRY sold about $77.0K of CVS on May 20, 2026; 1 other insider sold within 30 days and 1,110 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 19, 2026.
- The trade is 14.7% of the 5,415,633 shares held after it.
- 1 other insider sold within 30 days.
- 1,110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ROBBINS LARRY sold about $74.6M of CVS on May 20, 2026; 1 other insider sold within 30 days and 1,110 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 19, 2026.
- The trade is 2.9% of the 5,262,942 shares held after it.
- 1 other insider sold within 30 days.
- 1,110 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director ROBBINS LARRY sold about $14.5M of CVS on May 20, 2026; 1 other insider sold within 30 days and 1,110 funds added in the latest 13F quarter.62 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$323.7M over 180 days
below 98% of Wholesale & Retail
Congress
1 member bought in the last year
the lowest in Wholesale & Retail
Funds
1,110 funds bought in last quarter
more than 98% of Wholesale & Retail
Revenue
+7.8% year over year
more than 66% of Wholesale & Retail
Margin
0.4% net margin
below 60% of Wholesale & Retail
Buybacks
no share repurchases reported
Short interest
1.3% of the float short (float per yahoo 2026-10-26) · 1.7 days to cover · settled 2026-09-30
below 63% of Wholesale & Retail
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 8 in the prior 90
Why it matters
The absence is the signal: 8 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch CVS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+17.6%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CVS: institutional holders (13F)
13F holdings, latest reported quarter
123,223,409 sh
$12.7B
83,315,369 sh
$8.6B
74,951,955 sh
$7.8B
60,283,408 sh
$6.2B
50,012,765 sh
$5.2B
Congress trades in CVS
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-11-21 · disclosed 28 days later
$1,001 - $15,000
Sold 2025-11-21 · disclosed 175 days later
$1,001 - $15,000
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CVS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CVS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares U.S. Healthcare Providers ETF
$174.3M position · as of 2026-06-30
14.8%
Select Health Care Services Portfolio
$104.7M position · as of 2026-05-31
13.0%
Clipper Fund
$80.8M position · as of 2026-06-30
5.5%
Davis Balanced Fund
$17.0M position · as of 2026-06-30
5.3%
Davis Select U.S. Equity ETF
$67.1M position · as of 2026-07-31
5.3%
Davis New York Venture Fund
$399.2M position · as of 2026-07-31
5.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Cvs Health Pac
Cycle 2026 · $1,192K spent
$1.3M
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Karen SLynch
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$21.6M
$7.5M
$9.3M
+25%
+26%
2022
$21.3M
$23.8M
$12.2M
+43%
+24%
2021
$20.4M
$66.3M
$11.9M
+55%
+26%
2020
$3.8M
$52.8M
n/a
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $323.7M sold by insiders over 180 days, 1,110 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
CVS financials
Revenue growth
+7.8%
XBRL, annual
Net margin
0.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$415.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CVS
| FY Dec 2025 | $402.1B |
| FY Dec 2024 | $372.8B |
| FY Dec 2023 | $357.8B |
| FY Dec 2022 | $322.5B |
| FY Dec 2021 | $292.1B |
| Jun 2026 | $106.1B |
| Mar 2026 | $100.4B |
| Dec 2025 | $105.7B |
| Sep 2025 | $102.9B |
| Jun 2025 | $98.9B |
| Mar 2025 | $94.6B |
| Dec 2024 | $97.7B |
| Sep 2024 | $95.4B |
At each fiscal year end
Single quarter
Net margin, TTM
+1.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CVS
| FY Dec 2025 | +0.4% |
| FY Dec 2024 | +1.2% |
| FY Dec 2023 | +2.3% |
| FY Dec 2022 | +1.3% |
| FY Dec 2021 | +2.7% |
| Jun 2026 | +2.8% |
| Mar 2026 | +2.9% |
| Dec 2025 | +2.8% |
| Sep 2025 | -3.9% |
| Jun 2025 | +1.0% |
| Mar 2025 | +1.9% |
| Dec 2024 | +1.7% |
| Sep 2024 | +0.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$11.8B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CVS
| FY Dec 2025 | $7.8B |
| FY Dec 2024 | $6.3B |
| FY Dec 2023 | $10.4B |
| FY Dec 2022 | $13.4B |
| FY Dec 2021 | $15.7B |
| Jun 2026 | $5.7B |
| Mar 2026 | $3.4B |
| Dec 2025 | $2.6B |
| Sep 2025 | $98.0M |
| Jun 2025 | $1.3B |
| Mar 2025 | $3.8B |
| Dec 2024 | $1.1B |
| Sep 2024 | -$1.4B |
At each fiscal year end
Single quarter
Debt to equity
0.75x
long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end); equity 2026-06-30
Debt to equity CVS
| FY Dec 2025 | 0.80x |
| FY Dec 2024 | 0.83x |
| FY Dec 2023 | 0.77x |
| FY Dec 2022 | 0.71x |
| FY Dec 2021 | 0.70x |
| Jun 2026 | 0.75x |
| Mar 2026 | 0.78x |
| Dec 2025 | 0.80x |
| Sep 2025 | 0.85x |
| Jun 2025 | 0.78x |
| Mar 2025 | 0.78x |
| Dec 2024 | 0.83x |
| Sep 2024 | 0.81x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.25x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end)
Cash flow to debt CVS
| FY Dec 2025 | 0.18x |
| FY Dec 2024 | 0.15x |
| FY Dec 2023 | 0.23x |
| FY Dec 2022 | 0.32x |
| FY Dec 2021 | 0.35x |
| Jun 2026 | 0.25x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.18x |
| Sep 2025 | 0.15x |
| Jun 2025 | 0.13x |
| Mar 2025 | 0.15x |
| Dec 2024 | 0.15x |
| Sep 2024 | 0.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+6.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CVS
| FY Dec 2025 | +2.3% |
| FY Dec 2024 | +6.1% |
| FY Dec 2023 | +11.3% |
| FY Dec 2022 | +5.9% |
| FY Dec 2021 | +11.1% |
| Jun 2026 | +6.2% |
| Mar 2026 | +3.8% |
| Dec 2025 | +2.3% |
| Sep 2025 | +0.6% |
| Jun 2025 | +5.9% |
| Mar 2025 | +7.0% |
| Dec 2024 | +6.1% |
| Sep 2024 | +6.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CVS
| FY Dec 2025 | +0.7% |
| FY Dec 2024 | +1.8% |
| FY Dec 2023 | +3.5% |
| FY Dec 2022 | +1.9% |
| FY Dec 2021 | +3.5% |
| Jun 2026 | +1.9% |
| Mar 2026 | +1.2% |
| Dec 2025 | +0.7% |
| Sep 2025 | +0.2% |
| Jun 2025 | +1.8% |
| Mar 2025 | +2.1% |
| Dec 2024 | +1.8% |
| Sep 2024 | +2.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+5.5%
operating income after a 15.6% effective tax rate, over long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital CVS
| FY Dec 2025 | +3.0% |
| FY Dec 2024 | +4.9% |
| FY Dec 2023 | +8.4% |
| FY Dec 2022 | +5.3% |
| FY Dec 2021 | +8.7% |
| Jun 2026 | +5.5% |
| Mar 2026 | +3.9% |
| Dec 2025 | +3.0% |
| Sep 2025 | n/a |
| Jun 2025 | +5.0% |
| Mar 2025 | +5.6% |
| Dec 2024 | +4.9% |
| Sep 2024 | +5.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+5.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CVS
| FY Dec 2025 | +2.8% |
| FY Dec 2024 | +5.0% |
| FY Dec 2023 | +8.3% |
| FY Dec 2022 | +4.9% |
| FY Dec 2021 | +8.0% |
| Jun 2026 | +5.0% |
| Mar 2026 | +3.6% |
| Dec 2025 | +2.8% |
| Sep 2025 | +3.0% |
| Jun 2025 | +5.3% |
| Mar 2025 | +5.8% |
| Dec 2024 | +5.0% |
| Sep 2024 | +5.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
24.60x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CVS
| FY Dec 2025 | 56.69x |
| FY Dec 2024 | 12.23x |
| FY Dec 2023 | 12.20x |
| FY Dec 2022 | 28.76x |
| FY Dec 2021 | 17.14x |
| Jun 2026 | 27.22x |
| Mar 2026 | 31.36x |
| Dec 2025 | 56.69x |
| Sep 2025 | 193.31x |
| Jun 2025 | 19.21x |
| Mar 2025 | 16.13x |
| Dec 2024 | 12.23x |
| Sep 2024 | 15.92x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$167.7B
market value at close 2026-10-23 on 2026-07-29 shares, plus long-term 2026-06-30 plus current 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
Enterprise value CVS
| FY Dec 2025 | $152.8B |
| FY Dec 2024 | $110.5B |
| FY Dec 2023 | $152.3B |
| FY Dec 2022 | $160.0B |
| FY Dec 2021 | $179.0B |
| Jun 2026 | $180.1B |
| Mar 2026 | $142.4B |
| Dec 2025 | $152.8B |
| Sep 2025 | $148.3B |
| Jun 2025 | $135.8B |
| Mar 2025 | $135.6B |
| Dec 2024 | $110.5B |
| Sep 2024 | $132.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+9.8%
TTM free cash flow over market value at close 2026-10-23
FCF yield CVS
| FY Dec 2025 | +7.7% |
| FY Dec 2024 | +11.2% |
| FY Dec 2023 | +10.2% |
| FY Dec 2022 | +11.0% |
| FY Dec 2021 | +11.6% |
| Jun 2026 | +8.9% |
| Mar 2026 | +8.1% |
| Dec 2025 | +7.7% |
| Sep 2025 | +6.6% |
| Jun 2025 | +5.5% |
| Mar 2025 | +7.0% |
| Dec 2024 | +11.2% |
| Sep 2024 | +2.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
4.20x
P/E over trailing EPS growth of 6%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing CVS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.12x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 1.67x |
| Jun 2026 | 4.65x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $402.1B | $372.8B | $357.8B | $322.5B |
| Operating income | $4.7B | $8.5B | $13.7B | $8.0B |
| Net income | $1.8B | $4.6B | $8.3B | $4.3B |
| EPS (diluted) | 1.39 | 3.66 | 6.47 | 3.26 |
| Operating cash flow | $10.6B | $9.1B | $13.4B | $16.2B |
| Cash | $8.5B | $8.6B | $8.2B | $12.9B |
| Long-term debt | $60.5B | $60.5B | $58.6B | $50.5B |
| Buybacks | $0 | $3.0B | $2.0B | $3.5B |
| Dividends paid | $3.4B | $3.4B | $3.1B | $2.9B |
SEC XBRL, fiscal years, as known on 2026-10-27
CVS Stock Sonar score 6/7 axes
Find similar shapesCompareCVS ranks highest on risk and compliance (79th percentile) and growth (66th), and lowest on insider conviction (1st), among Wholesale & Retail peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CVS filings, in plain words
Are CVS Health insiders buying or selling CVS?
In the 180 days to 2026-10-27, CVS Health insiders were net sellers, a net $323.7M across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded CVS?
Yes. In the year to 2026-10-27, 1 House member disclosed buying CVS and 2 House members disclosed selling it; the latest on record is a sale by Dwight Evans dated 2025-11-21.
Read the full summary
In the 180 days to 2026-10-27, CVS Health insiders were net sellers of CVS, a net $323.7M across purchases and sales reported on Form 4 by 2 sellers. None of the 8 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-27, 1 member of Congress disclosed buying CVS and 2 members disclosed selling it; the latest on record is a sale by Dwight Evans dated 2025-11-21. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
